![]() BHC 10 Nov 2010 Estimated | Other | CA$1 Per Share |
![]() BHC 10 Nov 2010 Paid | Other | CA$1 Per Share |
![]() BHC 30 Aug 2010 Paid | Quarterly | CA$0.1 Per Share |
![]() BHC 31 May 2010 Paid | Quarterly | CA$0.1 Per Share |
![]() BHC 4 Mar 2010 Paid | Quarterly | CA$0.09 Per Share |
![]() BHC 30 Nov 2009 Paid | Quarterly | CA$0.09 Per Share |
30 Apr 2025 (21 Days) Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | 1.13 Cons. EPS | 1.16 EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 1.06 Cons. EPS | 1.13 EPS |
1 Aug 2024 Date | | 0.88 Cons. EPS | 0.04 EPS |
![]() BHC 10 Nov 2010 Estimated | Other | CA$1 Per Share |
![]() BHC 10 Nov 2010 Paid | Other | CA$1 Per Share |
![]() BHC 30 Aug 2010 Paid | Quarterly | CA$0.1 Per Share |
![]() BHC 31 May 2010 Paid | Quarterly | CA$0.1 Per Share |
![]() BHC 4 Mar 2010 Paid | Quarterly | CA$0.09 Per Share |
![]() BHC 30 Nov 2009 Paid | Quarterly | CA$0.09 Per Share |
30 Apr 2025 (21 Days) Date | | - Cons. EPS | - EPS |
20 Feb 2025 Date | | 1.13 Cons. EPS | 1.16 EPS |
31 Oct 2024 Date | | - Cons. EPS | - EPS |
30 Oct 2024 Date | | 1.06 Cons. EPS | 1.13 EPS |
1 Aug 2024 Date | | 0.88 Cons. EPS | 0.04 EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Thomas J. Appio CEO | TSX Exchange | CA0717341071 ISIN |
Canada Country | 20,270 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Bausch Health's diverse portfolio extends across various medical domains, including: